# A Study to Evaluate the Effects of Multiple Doses of FG-4592 on the Exposure, Safety and Tolerability and Effect of Warfarin in Healthy Subjects

> **NCT02252731** · PHASE1 · COMPLETED · sponsor: **Astellas Pharma Europe B.V.** · enrollment: 22 (actual)

## Conditions studied

- Pharmacokinetics of FG-4592
- Healthy Subjects

## Interventions

- **DRUG:** Warfarin
- **DRUG:** FG-4592

## Key facts

- **NCT ID:** NCT02252731
- **Lead sponsor:** Astellas Pharma Europe B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09
- **Primary completion:** 2013-11
- **Final completion:** 2013-11
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2014-09-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02252731

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02252731, "A Study to Evaluate the Effects of Multiple Doses of FG-4592 on the Exposure, Safety and Tolerability and Effect of Warfarin in Healthy Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02252731. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*